Business Description
EirGenix Inc
ISIN : TW0006589005
Total Employee Number:
199Description
EirGenix Inc is engaged in the research and development of biosimilars and new drugs, as well as biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Its products include CRM197 CARRIER PROTEIN, PRODUCT PIPELINE, COVID-19 ANTIGEN RAPID TEST. The revenue is derived from biopharmaceutical contract development and manufacturing services, sales of authorization and cooperative development, and sales of goods. Geographically, it operates in Japan, Taiwan, USA and Canada, Mainland China, Hong Kong, and Macao, and Europe, Others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.07 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -3.38 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.6 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12 | |||||
3-Year EPS without NRI Growth Rate | -89.8 | |||||
3-Year FCF Growth Rate | -12.4 | |||||
3-Year Book Growth Rate | -7.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.64 | |||||
9-Day RSI | 64.43 | |||||
14-Day RSI | 61.83 | |||||
3-1 Month Momentum % | -21.82 | |||||
6-1 Month Momentum % | -27.86 | |||||
12-1 Month Momentum % | -30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.73 | |||||
Quick Ratio | 3.33 | |||||
Cash Ratio | 2.9 | |||||
Days Inventory | 244.95 | |||||
Days Sales Outstanding | 56.12 | |||||
Days Payable | 37.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | -2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 19.28 | |||||
Operating Margin % | -83.91 | |||||
Net Margin % | -75.67 | |||||
EBITDA Margin % | -50.29 | |||||
FCF Margin % | -131.7 | |||||
OCF Margin % | 29.65 | |||||
ROE % | -8.77 | |||||
ROA % | -7.12 | |||||
ROIC % | -12.75 | |||||
3-Year ROIIC % | -17.4 | |||||
ROC (Joel Greenblatt) % | -14.31 | |||||
ROCE % | -7.62 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 17180 | |||||
PS Ratio | 14.94 | |||||
PB Ratio | 1.8 | |||||
Price-to-Tangible-Book | 1.9 | |||||
Price-to-Operating-Cash-Flow | 50.56 | |||||
EV-to-EBIT | -17.6 | |||||
EV-to-EBITDA | -26.18 | |||||
EV-to-Revenue | 13.17 | |||||
EV-to-FCF | -10 | |||||
Price-to-GF-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 7.77 | |||||
| Price-to-Net-Cash | 16.35 | |||||
Earnings Yield (Greenblatt) % | -5.68 | |||||
FCF Yield % | -8.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EirGenix Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,005.156 | ||
| EPS (TTM) (NT$) | -2.52 | ||
| Beta | -0.6812 | ||
| 3-Year Sharpe Ratio | -1.11 | ||
| 3-Year Sortino Ratio | -1.26 | ||
| Volatility % | 40.44 | ||
| 14-Day RSI | 61.83 | ||
| 14-Day ATR (NT$) | 1.929408 | ||
| 20-Day SMA (NT$) | 46.2475 | ||
| 12-1 Month Momentum % | -30 | ||
| 52-Week Range (NT$) | 40.15 - 84.3 | ||
| Shares Outstanding (Mil) | 302.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EirGenix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EirGenix Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
EirGenix Inc Frequently Asked Questions
What is EirGenix Inc(TPE:6589)'s stock price today?
The current price of TPE:6589 is NT$49.70. The 52 week high of TPE:6589 is NT$84.30 and 52 week low is NT$40.15.
When is next earnings date of EirGenix Inc(TPE:6589)?
The next earnings date of EirGenix Inc(TPE:6589) is .
Does EirGenix Inc(TPE:6589) pay dividends? If so, how much?
EirGenix Inc(TPE:6589) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| /C O R R E C T I O N -- EirGenix, Inc./ | 2025-11-12 | ||
| EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A | 2025-11-12 |
Articles on EirGenix Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers